Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Disc Medicine Yönetim

Yönetim kriter kontrolleri 3/4

Disc Medicine's CEO'su John Quisel, Feb2020 tarihinde atandı, in görev süresi 4.67 yıldır. in toplam yıllık tazminatı $ 903.46K olup, şirket hissesi ve opsiyonları dahil olmak üzere 62.2% maaş ve 37.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.24% ine doğrudan sahiptir ve bu hisseler $ 3.54M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.2 yıl ve 4 yıldır.

Anahtar bilgiler

John Quisel

İcra Kurulu Başkanı

US$903.5k

Toplam tazminat

CEO maaş yüzdesi	62.2%
CEO görev süresi	4.7yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.2yrs
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Aug 13

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Jun 14

Disc Medicine: What's Behind The Huge Rally

Jan 31

CEO Tazminat Analizi

John Quisel'un ücretlendirmesi Disc Medicine'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$91m
Mar 31 2024	n/a	n/a	-US$81m
Dec 31 2023	US$903k	US$562k	-US$76m
Sep 30 2023	n/a	n/a	-US$64m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$60m
Dec 31 2022	US$2m	US$476k	-US$47m
Sep 30 2022	n/a	n/a	-US$44m
Jun 30 2022	n/a	n/a	-US$37m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	US$2m	US$455k	-US$36m
Dec 31 2020	US$820k	US$373k	-US$21m

Tazminat ve Piyasa: John 'nin toplam tazminatı ($USD 903.46K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.54M ).

Tazminat ve Kazançlar: John 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

John Quisel (53 yo)

4.7yrs

Görev süresi

US$903,461

Tazminat

Dr. John D. Quisel, J.D., Ph D., Esq., serves as Independent Director of Gossamer Bio, Inc. since November 2023. He serves as Chief Executive Officer of Disc Medicine, Inc. since February 25, 2020 and serv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Donald Nicholson	Executive Chairman	5.5yrs	US$379.31k	0.052% $ 785.0k
John Quisel	CEO, President & Director	4.7yrs	US$903.46k	0.24% $ 3.7m
William Savage	Chief Medical Officer	3.2yrs	US$687.74k	0.14% $ 2.1m
Brian MacDonald	Founder & Chair of Scientific Advisory Board	7yrs	US$88.54k	0.052% $ 796.9k
Jean Franchi	Chief Financial Officer	less than a year	Veri yok	0.12% $ 1.9m
Jonathan Yu	Chief Opearating Officer	less than a year	US$816.54k	0.061% $ 930.1k
Rahul Khara	General Counsel	2.8yrs	Veri yok	0.047% $ 718.5k
Srikanth Venkatraman	Senior VP & Head of Chemistry	no data	Veri yok	Veri yok
Hua Yang	Senior Vice President & Head of Early Development and Clinical Pharmacology	1.7yrs	Veri yok	Veri yok
Pamela Stephenson	Chief Commercial Officer	less than a year	Veri yok	0.12% $ 1.9m
Sonia Razzetti	Senior Vice President of Quality	less than a year	Veri yok	Veri yok
Melanie Chin	VP of Clinical Development & Head of Medical Affairs	less than a year	Veri yok	Veri yok

1.2yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: IRON 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Donald Nicholson	Executive Chairman	5.5yrs	US$379.31k	0.052% $ 785.0k
John Quisel	CEO, President & Director	4.7yrs	US$903.46k	0.24% $ 3.7m
Brian MacDonald	Founder & Chair of Scientific Advisory Board	less than a year	US$88.54k	0.052% $ 796.9k
Kevin Bitterman	Independent Director	6.9yrs	US$268.31k	0% $ 0
Tomas Ganz	Member of Scientific Advisory Board	4yrs	Veri yok	Veri yok
Mona Ashiya	Independent Director	3.1yrs	US$264.31k	0% $ 0
Liam Ratcliffe	Independent Director	5.1yrs	US$266.81k	0% $ 0
Elizabeta Nemeth	Member of Scientific Advisory Board	4yrs	Veri yok	Veri yok
Mark Chin	Independent Director	3.1yrs	US$262.81k	0% $ 0
William White	Independent Director	3.8yrs	US$270.31k	0% $ 0
Stefano Rivella	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Mark Fleming	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

4.0yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IRON 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Disc Medicine Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Disc Medicine, Inc. Announces Appointment of Steve Caffé as Chief Regulatory Officer

Disc Medicine, Inc., Annual General Meeting, Jun 12, 2024

Independent Director notifies of intention to sell stock

Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Recent updates

Disc Medicine, Inc. Announces Appointment of Steve Caffé as Chief Regulatory Officer

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Disc Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $177.984 million.

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine, Inc., Annual General Meeting, Jun 12, 2024

Independent Director notifies of intention to sell stock

Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria (EPP)

New major risk - Revenue and earnings growth

Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer

Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Key Executive notifies of intention to sell stock

Disc Medicine: What's Behind The Huge Rally

Key Executive notifies of intention to sell stock

Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Independent Director notifies of intention to sell stock

Disc Presents Initial Positive Data from Ongoing Phase 1B/2 Trial of Disc-0974 in Patients with Myelofibrosis (Mf) and Anemia At the 65Th American Society of Hematology (Ash) Annual Meeting

General Counsel notifies of intention to sell stock

General Counsel exercised options and sold US$176k worth of stock

General Counsel notifies of intention to sell stock

Disc Medicine Announces Departure of Joanne Bryce as Chief Financial Officer

Disc Medicine Announces Departure of Joanne Bryce as Chief Financial Officer

Disc Medicine, Inc. Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

Chief Financial Officer notifies of intention to sell stock

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia

Chief Financial Officer notifies of intention to sell stock

New minor risk - Share price stability

Disc Medicine, Inc. Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria at European Hematology Association (EHA) 2023 Congress

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria at European Hematology Association 2023 Congress

Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

No independent directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş